# Research Debate Transcript — IO Biotech Phase 3 Melanoma Readout (IOBT)

PAPER-TRADING SIMULATION ONLY. NOT FINANCIAL ADVICE.

Strategy: `three-round-panel`. Personas: bull (sonnet), bear (sonnet), quant (opus).
Synthesizer: opus. Run: 2026-07-25T14:42:34Z.

Dossier facts in scope: IO Biotech IO102-IO103 plus Keytruda (pembrolizumab) Phase 3
melanoma readout due August 2026; early reads "narrowly missed statistical
significance threshold"; impact window 2026-08-15; ticker IOBT; single source
"10 clinical trials to watch in H2 2026" (BioPharma Dive,
https://www.biopharmadive.com/news/biotech-pharma-clinical-trials-watch-2026/808255/,
accessed 2026-07-23).

Relevant institutional memory injected: a prior lesson from the SPCX opportunity
(freshly-IPO'd tickers are a distinct data-risk category — verify priceability before
scheduling, not just a stale reference print).

---

## Round 1 — Independent research

### Bull

This is a binary Phase 3 catalyst (IO102-IO103 + Keytruda vs. Keytruda alone in
melanoma) with a hard date — impact window 2026-08-15, per the dossier. Binary trial
readouts are exactly the kind of event that moves a small-cap biotech 30-100%+ in a
single session, in either direction. The dossier itself flags that early reads
"narrowly missed statistical significance threshold" — that's a leak/rumor, not the
final locked readout. Thesis: if that soft signal has already been chewed on by the
market since the BioPharma Dive piece (accessed 2026-07-23), IOBT's price may already
reflect a lowered bar. A "narrow miss" on an interim/early read is very different from
the final powered analysis — trials that miss narrowly on early looks can still cross
the line at final readout due to maturing event curves, especially in immuno-oncology
where PFS/OS curves separate late. That asymmetry — priced for disappointment,
catalyst still open — is the trade.

Evidence: dossier facts (event.type=product, credible trade-press source, readout due
August 2026, impact window 2026-08-15). General knowledge (flagged, not
dossier-sourced): IO102-IO103 is a T-cell-activating cancer vaccine (targets IDO1 and
PD-L1 expressing cells) combined with pembrolizumab in first-line advanced melanoma —
mechanistically rational combo. IOBT is a small-float, single-asset biotech, the
profile that produces outsized catalyst moves.

Proposed action: long, structured for a binary event. Entry 5-10 trading days before
Aug 15 (~Aug 1-8), scaling in. Instrument: defined-risk options (long call/call
spread) over common stock; fallback small common-stock position sized for full loss.
Exit within 1-3 sessions after the Aug 15 print.

Confidence: 5/10 (moderate-low) — long the event's volatility/optionality more than
confident in a beat. Steelman of the bear case: "narrowly missed statistical
significance" on an early read is a real negative signal; a confirmed miss could send
IOBT down 50-70%. Still likes it as a small, defined-risk swing on optionality, not a
conviction long.

### Bear

The "narrow miss" framing is the whole ballgame, and it cuts against the bull. In
Phase 3 oncology, a narrow miss on an early/interim read is not "almost a win" — it's
the single most common precursor to a confirmed primary-endpoint failure at final
analysis (regression to the mean, alpha-spending penalties, curves rarely separate
more later than at interim).

What's priced in: IOBT is a single-asset clinical-stage biotech with a binary catalyst
on the calendar — exactly the profile where options-implied vol and short interest are
already elevated well ahead of readout. No edge in trading the obvious binary unless
we have superior information, which we don't — a single trade-press listicle, not a
primary source (no clinicaltrials.gov ID, no company PR, no SEC 8-K).

Failure modes: single-source, no primary citation (detail could be wrong/stale/garbled);
data already priced or leaked; binary gap risk (30-70% moves, stops meaningless);
timeline slip (biotech readouts routinely slip quarters); liquidity/float unconfirmed.

Recommendation: PASS, or at most a small, defined-risk options structure sized to
survive a 50%+ gap, entered only after confirming primary-source trial-registry data.
Confidence in "pass as base case": 75%.

### Quant

Ran `toa price IOBT <ts> --provider twelvedata` on three separate dates
(2026-07-22/23/24): all returned `MarketDataUnavailable: HTTP 400`. Default provider
(no flag) returned a fabricated stub: `{"price": 295.08, "source": "stub:deterministic"}`
— nonsense for a sub-USD-5 microcap, not a real quote. Control test on AAPL same
provider/timestamps succeeded normally (e.g. `AAPL 2026-07-22T15:30Z -> {"price":
325.76501, "source": "twelvedata..."}`), proving the failure is IOBT-specific, not a
transient provider outage. HTTP 400 (vs. "no bar available") indicates IOBT is absent
from the provider's symbol universe entirely — structurally, like the documented .NS
and .PA gaps.

Base rate: Phase 3 oncology success overall ~35-40%; melanoma checkpoint-combo add-ons
worse (strong Keytruda-monotherapy control arm), call it 25-35% baseline. The dossier's
decisive fact ("narrowly missed significance at early reads") is a negative signal, not
a coin flip — interims are usually powered on immature events; combos that can't
separate early rarely gain separation later, and alpha already spent at interim raises
the final bar. Estimate: P(clear win)=0.20, P(ambiguous)=0.25, P(clear miss)=0.55.

Magnitude: clear win +80-150% (call +100%); ambiguous -20%; clear miss -50-80% (call
-65%).

EV: Long EV = 0.20(+100) + 0.25(-20) + 0.55(-65) = +20 - 5 - 35.75 = **-20.8%**. Short
nominal EV ≈ +20.8% gross, net of costs (bid-ask 2-4%, event-day slippage 3-5%, borrow
10-40% annualized ~2% over three weeks) ≈ **+10-14% gross of the tail** — but the
short's adverse tail (squeeze, 20% probability of a large loss) requires small Kelly
sizing (~2-3% of book). All of this is moot: multiply by P(executable)≈0 and EV
collapses to zero, with nonzero probability of a fake fill at the USD 295 stub, which
is worse than no trade (pollutes the P/L record with a fabricated result).

Recommendation: PASS. Confidence 85%. Notes this is the third such coverage-gap case in
memory (.NS, .PA, now IOBT microcap) and recommends a coverage pre-check at scout time.

---

## Round 2 — Rebuttal

### Bull

Partial concession to Bear on the "narrow miss" argument: no primary trial-registry
data to counter regression-to-mean; drops "market may be under-pricing the tail" as
speculative/unsourced. Still holds that interim ≠ final isn't near-certain failure, but
doesn't dispute the bearish shift.

On Quant's coverage finding: dispositive, not just informative. HTTP 400 across three
dates with a clean AAPL control, plus a fabricated $295.08 stub, is a structural gap —
same pattern as the prior .NS and .PA findings now in memory. This kills the proposal
as designed: no priceable ticker means no simulated fills, stops, or exits. Also notes
the originally proposed options structure was never realistic anyway (illiquid microcap
options chains), which the Bear's "stops are meaningless" point also implicitly nails.

What would change his mind: (a) confirmation the ticker is priceable via a real
provider path, (b) a primary-source trial registry update on the interim read's actual
magnitude/design.

Final position: collapses to PASS, full stop — not "conditional long" — because the
blocking issue is infrastructural, not a risk-sizing choice. Confidence in PASS: 8/10.

### Bear

Quant's P(clear miss)=0.55 is directional confirmation of the Round 1 thesis (same
base-rate logic, now numeric) but doesn't over-credit it — it's still the Quant's
prior, not a trial-registry fact.

On Bull's "curves can separate later": real IO phenomenon in general, but a hypothesis
with no citation specific to this trial's mechanism, endpoint, or interim design.
Without knowing the interim analysis type (futility boundary? blinded/unblinded peek?),
"curves could still separate" is unfalsifiable optimism — doesn't move the needle.

On the coverage finding: decisive regardless of thesis merit. Even fully buying the
Bull's separation story, no position can be executed, sized, hedged, or exited in a name
the system can't price — and the fabricated $295.08 stub is "actively dangerous" (could
silently corrupt automated sizing/stop logic).

Final position: PASS, confidence 90% (up from 75%) — the thesis-level skepticism and
the infrastructure gap are independently sufficient; the coverage finding is the final
nail but would have stood at PASS on thesis alone. Would reconsider only if BOTH
coverage is confirmed fixed with a real quote AND a primary trial-registry source
clarifies the interim analysis design.

### Quant

Convergence with Bear: P(clear miss)=0.55 was derived independently and lands on the
same side — two independent routes to "narrow miss at interim skews negative" is real
corroboration. Matches Bear's evidence complaint: the only source is a listicle, no
trial-registry primary citation, so the prior is doing nearly all the work — exactly
why a 30-100% binary shouldn't be priced off it.

On Bull's "late curve separation": mechanistically plausible for IO combos, but the
dossier has zero survival-curve, hazard-ratio, or timepoint data to condition on.
Maximum concession: shift ~3pp from clear-miss into ambiguous → P(win)=0.20,
P(ambiguous)=0.28, P(miss)=0.52. Long EV moves from ≈-20.8% to ≈-19%. Sign unchanged,
decision unchanged — a non-actionable update.

Coverage gate reaffirmed unchanged: HTTP 400 on all three dates vs. passing AAPL
control; P(executable)≈0. Bull's options structure makes this strictly worse — no
options-chain pricing at all in this harness, so "defined risk" is actually undefined
risk (no entry fill, no exit fill, no simulated P/L).

Final recommendation: unconditional PASS, confidence 88% (up from 85% — Bear's source
critique reinforces it). Revisit only if BOTH: `toa price IOBT` returns a real quote
for a pre-event date with an AAPL control passing in the same run, AND a primary
trial-registry citation replaces the listicle.

---

## Round 3 — Synthesis (opus)

**Hypothesis**
- Statement: IO Biotech's Phase 3 melanoma readout (IO102-IO103 + pembrolizumab,
  window 2026-08-15) is not a tradeable opportunity in this harness: IOBT has no price
  coverage in the available data provider, and the underlying thesis skews negative (an
  early "narrow miss" is a recognized precursor to primary-endpoint failure), leaving no
  positive-expectancy long and no safely sizable short.
- Direction: no-trade
- Confidence: 87

**Plan**
No position opened. No entry, no exit, no size, no options structure — the bull's
proposed long is withdrawn. Revisit only if ALL of:
1. Coverage restored: `toa price IOBT <ts> --provider twelvedata` returns a real quote,
   with an AAPL control passing in the same run. The default no-flag provider is
   explicitly rejected — it returned a fabricated USD 295.08 stub for a sub-USD-5
   microcap.
2. Primary source: the BioPharma Dive listicle is replaced by a trial-registry entry
   (NCT ID) or company PR/8-K specifying the interim analysis type, primary endpoint,
   and the actual margin by which significance was missed.
3. Liquidity/instrument check: if a short or options structure is contemplated, confirm
   borrow availability and options-chain pricing exist in the harness — currently
   neither does.
If coverage is fixed but the source remains a listicle, still pass.

**Dissent**
The unresolved disagreement is about tail upside, not the decision. Bull maintains an
interim narrow miss is not near-certain failure and that late curve separation is
mechanistically plausible; Bear rejects this as unfalsifiable absent trial-design
specifics; Quant priced the concession at only 3pp shifted from clear-miss to ambiguous
(long EV -20.8% → -19%). The PASS is unanimous but over-determined: the coverage gate
did the work, and the thesis question was never fully settled. Flag for post-mortem: if
IOBT prints a clear win on Aug 15, the correct lesson is "coverage gate was right,
thesis EV possibly mis-signed," not "the panel was right." Also flag that no persona
quantified timeline-slip risk (readout landing outside the window), raised by the bear
in Round 1 and never revisited.

**Summary**
Three personas converged independently on PASS via two separable routes. Decisive
route: IOBT returns HTTP 400 MarketDataUnavailable across three dates while an AAPL
control succeeds, matching previously documented structural coverage gaps (.NS, .PA) —
P(executable)≈0, no fill/stop/exit can be simulated. Secondary route: the catalyst
rests on a single non-primary listicle reporting an early narrow miss on significance,
which historically precedes confirmed endpoint failure; modeled long EV ≈ -19 to -21%,
and the nominally positive short EV carries an unbounded gap tail in a thin microcap
with no options-chain pricing available. Bull withdrew his defined-risk long as
unimplementable. No position opened; revisit requires both real quote coverage and a
primary trial-registry source.
